[email protected] +44 20 8123 2220 (UK) +1 732 587 5005 (US) Contact Us | FAQ |

Gastric Cancer Drugs Global Market Report 2020. Including: 1) By Type: Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab 2) By End User: Hospitals, Clinics, Others 3) By Route of Administration: Oral, Parenteral. Covering: Eli Lilly and company, Novartis, Merck KGaA, Otsuka Pharmaceutical, F. Hoffmann-La Roche

December 2019 | 200 pages | ID: G4D12AD02C02EN
The Business Research Company

US$ 4,000.00

E-mail Delivery (PDF)

Download PDF Leaflet

Wire Transfer
Checkout Later
Need Help? Ask a Question
If ordered it will be delivered within 3-5 business days.

Gastric Cancer Drugs Market Global Report 2020 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the global gastric cancer drugs market.

REASONS TO PURCHASE
  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market research findings.
  • Benchmark performance against key competitors.
  • Utilize the relationships between key data sets for superior strategizing.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 3-5 working days of order.
DESCRIPTION:

Where is the largest and fastest growing market for the gastric cancer drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The Gastric Cancer Drugs Market Global Report from The Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market.
  • The Market Characteristics section of the report defines and explains the market.
  • The Market Size section gives the market size ($b) covering both the historic growth of the market and forecasting the future. Drivers and restraints looks at the external factors supporting and controlling the growth of the market.
  • Market Segmentations break down market into sub markets.
  • The Regional and Country section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers all the regions, key developed countries and major emerging markets. It draws comparisons with country populations and economies to understand the importance of the market by country and how this is changing.
  • Competitive Landscape gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The Trends and Strategies section highlights the likely future developments in the market and suggests approaches companies can take to exploit this.
SCOPE

Markets Covered: 1) By Type: Doxorubicin Hydrochloride, Sunitinib, Docetaxel, Mitomycin, Fluorouracil, Imatinib, Trastuzumab 2) By End User: Hospitals, Clinics, Others 3) By Route of Administration: Oral, Parenteral

Companies Mentioned: Eli Lilly and company, Novartis, Merck KGaA, Otsuka Pharmaceutical, F. Hoffmann-La Roche

Countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA

Regions: Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Time Series: Five years historic and forecast.

Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
1. EXECUTIVE SUMMARY

2. GASTRIC CANCER DRUGS MARKET CHARACTERISTICS

3. GASTRIC CANCER DRUGS MARKET SIZE AND GROWTH

3.1. Global Gastric Cancer Drugs Historic Market, 2015 - 2019, $ Billion
  3.1.1. Drivers Of The Market
  3.1.2. Restraints On The Market
3.2. Global Gastric Cancer Drugs Forecast Market, 2019 - 2022F, 2025F, 2030F, $ Billion
  3.2.1. Drivers Of The Market
  3.2.2. Restraints On the Market

4. GASTRIC CANCER DRUGS MARKET SEGMENTATION

4.1. Global Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
Doxorubicin Hydrochloride
Sunitinib
Docetaxel
Mitomycin
Fluorouracil
Imatinib
Trastuzumab
4.2. Global Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
Hospitals
Clinics
Others
4.3. Global Gastric Cancer Drugs Market, Segmentation By Route of Administration, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
Oral
Parenteral

5. GASTRIC CANCER DRUGS MARKET REGIONAL AND COUNTRY ANALYSIS

5.1. Global Gastric Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
5.2. Global Gastric Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

6. ASIA-PACIFIC GASTRIC CANCER DRUGS MARKET

6.1. Asia-Pacific Gastric Cancer Drugs Market Overview
6.2. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
6.3. Asia-Pacific Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

7. CHINA GASTRIC CANCER DRUGS MARKET

7.1. China Gastric Cancer Drugs Market Overview
7.2. China Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion
7.3. China Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F,$ Billion

8. INDIA GASTRIC CANCER DRUGS MARKET

8.1. India Gastric Cancer Drugs Market Overview
8.2. India Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
8.3. India Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

9. JAPAN GASTRIC CANCER DRUGS MARKET

9.1. Japan Gastric Cancer Drugs Market Overview
9.2. Japan Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
9.3. Japan Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

10. AUSTRALIA GASTRIC CANCER DRUGS MARKET

10.1. Australia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
10.2. Australia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

11. INDONESIA GASTRIC CANCER DRUGS MARKET

11.1. Indonesia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
11.2. Indonesia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

12. SOUTH KOREA GASTRIC CANCER DRUGS MARKET

12.1. South Korea Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
12.2. South Korea Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

13. WESTERN EUROPE GASTRIC CANCER DRUGS MARKET

13.1. Western Europe Gastric Cancer Drugs Market Overview
13.2. Western Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
13.3. Western Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

14. UK GASTRIC CANCER DRUGS MARKET

14.1. UK Gastric Cancer Drugs Market Overview
14.2. UK Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
14.3. UK Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

15. GERMANY GASTRIC CANCER DRUGS MARKET

15.1. Germany Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
15.2. Germany Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

16. FRANCE GASTRIC CANCER DRUGS MARKET

16.4. France Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
16.5. France Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

17. EASTERN EUROPE GASTRIC CANCER DRUGS MARKET

17.1. Eastern Europe Gastric Cancer Drugs Market Overview
17.2. Eastern Europe Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
17.3. Eastern Europe Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

18. RUSSIA GASTRIC CANCER DRUGS MARKET

18.1. Russia Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
18.2. Russia Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

19. NORTH AMERICA GASTRIC CANCER DRUGS MARKET

19.1. North America Gastric Cancer Drugs Market Overview
19.2. North America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
19.3. North America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

20. USA GASTRIC CANCER DRUGS MARKET

20.1. USA Gastric Cancer Drugs Market Overview
20.2. USA Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
20.3. USA Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

21. SOUTH AMERICA GASTRIC CANCER DRUGS MARKET

21.1. South America Gastric Cancer Drugs Market Overview
21.2. South America Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
21.3. South America Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

22. BRAZIL GASTRIC CANCER DRUGS MARKET

22.1. Brazil Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
22.2. Brazil Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

23. MIDDLE EAST GASTRIC CANCER DRUGS MARKET

23.1. Middle East Gastric Cancer Drugs Market Overview
23.2. Middle East Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
23.3. Middle East Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

24. AFRICA GASTRIC CANCER DRUGS MARKET

24.1. Africa Gastric Cancer Drugs Market Overview
24.2. Africa Gastric Cancer Drugs Market, Segmentation By Type, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion
24.3. Africa Gastric Cancer Drugs Market, Segmentation By End User, Historic and Forecast, 2015-2019, 2022F, 2025F, 2030F, $ Billion

25. GASTRIC CANCER DRUGS MARKET COMPETITIVE LANDSCAPE AND COMPANY PROFILES

25.1. Gastric Cancer Drugs Market Competitive Landscape
25.2. Gastric Cancer Drugs Market Company Profiles
  25.2.1. Eli Lilly and company
    25.2.1.1. Overview
    25.2.1.2. Products and Services
    25.2.1.3. Strategy
    25.2.1.4. Financial Performance
  25.2.2. Novartis
    25.2.2.1. Overview
    25.2.2.2. Products and Services
    25.2.2.3. Strategy
    25.2.2.4. Financial Performance
  25.2.3. Merck KGaA
    25.2.3.1. Overview
    25.2.3.2. Products and Services
    25.2.3.3. Strategy
    25.2.3.4. Financial Performance
  25.2.4. Otsuka Pharmaceutical
    25.2.4.1. Overview
    25.2.4.2. Products and Services
    25.2.4.3. Strategy
    25.2.4.4. Financial Performance
  25.2.5. F. Hoffmann-La Roche
    25.2.5.1. Overview
    25.2.5.2. Products and Services
    25.2.5.3. Strategy
    25.2.5.4. Financial Performance

26. KEY MERGERS AND ACQUISITIONS IN THE GASTRIC CANCER DRUGS MARKET

27. GASTRIC CANCER DRUGS MARKET TRENDS AND STRATEGIES

28. PRODUCT PIPELINE ANALYSIS

29. GASTRIC CANCER DRUGS MARKET FUTURE OUTLOOK AND POTENTIAL ANALYSIS

30. APPENDIX

30.1. Abbreviations
30.2. Currencies
30.3. Research Inquiries
30.4. The Business Research Company
30.5. Copyright And Disclaimer


More Publications